Development and validation of serological methods for human vaccine potency testing: Case study of an anthrax vaccine

Procedia in Vaccinology

Volumn 5, Issue , 2011, Pages 213-220

  Arciniega, Juan L ^a   Domínguez Castillo, Rocío I ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Anthrax; Potency testing; TNA

Indexed keywords

ANTHRAX VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG MANUFACTURE; DRUG POTENCY; DRUG QUALITY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROLOGY; TOXIN NEUTRALIZATION ASSAY; TREATMENT RESPONSE;

EID: 84555217934     PISSN: None     EISSN: 1877282X     Source Type: Journal    
DOI: 10.1016/j.provac.2011.10.021     Document Type: Article

References (20)

1. Friedlander AM, Little SF. Advances in the development of next-generation anthrax vaccines Vaccine 2009; 27(S4):D28-32.
2. Emergent Biosolutions. BioThrax (Anthrax Vaccine Adsorbed) 2008; package insert. Lansing, MI.
3. Groseclose S.L., Knowles C.M., Hall P.A., Adams D.A., Anderson W.J., Snavely K., et al. Summary of notifiable diseases-United States, 1998. MMWR 1999, 47(53):1-93.
4. McNabb S.J.N., Jajosky R.A., Hall-Baker P.A., Adams D.A., Sharp P., Worshams C., et al. Summary of notifiable diseases-United States, 2006. MMWR. 2008, 55(53):1-92.
5. Baillie L.W. Is new always better than old?.: The development of human vaccines for anthrax. Hum. Vaccin. 2009, 5(12):806-816.
6. Young J.A., Collier R.J., Anthrax, Toxin: Receptor binding, internalization, pore formation, and translocation. Ann Rev Biochem 2007, 76:243-265.
7. U.S. Code of Federal Regulations. 21 CFR 601.2. Title 21-Food and Drugs; Chapter I-Food and Drug Administration, Department of Health and Human Services; Subchapter F-Biologics; Part 601-Licensing; Subpart A-General Provisions. Available at: http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?sid=95daa97e9bf648acd1293c22b1b9a266&c=ecfr&tpl=/ecfrbrowse/Title21/21cfrv7_02.tpl.
8. U. S. Pharmacopeial Convention, and U. S. Pharmacopeia. 2010. United States Pharmacopeia (USP 33 NF 28). United States Pharmacopeia, Rockville, MD.
9. Kobiler D., Gozes Y., Rosenerg H., Marcus D., Reuveny S., Altoboum Z. Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization. Infect Immun 2002, 70(2):544-560.
10. Pombo M., Berthold I., Gingrich E., Jaramillo M., Leef M., Sirota L., et al. Validation of an anti-PA-ELISA for the potency testing of anthrax vaccine in mice. Biologicals 2005, 32(3):157-163.
11. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. 2005. Validation of Analytical Procedures: Text and Methodology (Q2R1). Geneva, Switzerland.
12. Parreiras P.M., Sirota L.A., Wagner L.D., Menzies S.L., Arciniega J.L. Comparability of ELISA and toxin neutralization to measure immunogenicity of Protective Antigen in mice, as part of a potency test for anthrax vaccines. Vaccine 2009, 27(33):4537-4542.
13. Bland M.J., Altman D.G. Measuring agreement in method comparison studies. Stat Methods Med Res 1999, 8(2):135-160.
14. Jiang G., Joshi S.B., Peek L.J., Brandau D.T., Huang J., Ferriter M.S., et al. Anthrax vaccine powder formulations for nasal mucosal delivery. J Pharm Sci 2006, 95(1):80-96.
15. Radha C., Salotra P., Bhat R., Bhatnagar R. Thermostabilization of protective antigen--the binding component of anthrax lethal toxin. J Biotechnol 1996, 50(2-3):235-242.
16. Singh S, Ahuja N, Chauhan V, Rajasekaran E, Mohsin Waheed S, Bhat R, Bhatnagar R. Gln277 and Phe554 residues are involved in thermal inactivation of protective antigen of Bacillus anthracis. Biochem Biophys Res Commun 2002;296(5):1058-1062.
17. Castelán-Vega JA, Sirota L, Parreiras P, Arciniega JL. Comparison of ELISA and toxin neutralization to detect changes in immunogenicity of anthrax vaccine in mice. Vaccine Second Global Congress 2008; Boston, MA. Abstract P21.
18. Reuveny S., White M.D., Adar Y.Y., Kafri Y., Altboum Z., Gozes Y., Kobiler D., Shafferman A., Velan B. Search for correlates of protective immunity conferred by anthrax vaccine. Infect Immun 2001, 69(5):2888-2893.
19. U.S. Code of Federal Regulations. 21 CFR 601.90. Title 21-Food and Drugs; Chapter I-Food and Drug Administration, Department of Health and Human Services; Subchapter F-Biologics; Part 601-Licensing; Subpart H-Approval of Biological Products When Human Efficacy Studies Are Not Ethical or Feasible. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=601&showFR=1&subpartNode=21:7.0.1.1.2.8.
20. Omland K.S., Brys A., Lansky D., Clement K., Lynn F. Participating Laboratories. Interlaboratory comparison of the anthrax lethal toxin neutralization assay used to assess functional antibodies in multiple species. Clin Vaccine Immunol 2008, 15(6):946-953.